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INTRODUCTION
Lymphoma, also referred to as lymphosarcoma
(LSA) or malignant lymphoma, is one of the most pre-
valent neoplasms in the dog. It accounts for 7% to 24%
of all canine tumors and up to 83% of all canine he-
matopoietic malignancies (Vail and Young, 2007; Vail,
2010). LSA arises due to the proliferation of malignant
lymphoid cells – usually in lymphoid tissue, such as
lymph nodes, liver or spleen, but the tumor may origi-
nate in practically any tissue (Vail and Young, 2007;
Couto, 2009; Vail, 2010). This origin from solid organs
distinguishes LSA from lymphoid leukemia, as the lat-
ter arises from bone marrow (Couto, 2009). The etiology
of LSA is considered to be multifactorial. Several envi-
ronmental, infectious, immune-mediated and genetic
factors are associated with a higher risk of developing
LSA (Keller, 1992; Gavazza et al., 2001; Blackwood et
al., 2004; Farinha and Gascoyne, 2005; Modiano et al.,
2005; Brunker and Hoover, 2007; Santoro et al., 2007;
Huang et al., 2012). Affected animals are mainly middle-
aged to older dogs, and there is no sex predilection (Pa-
rodi et al., 1968).
There are four different anatomical forms: multi-
centric (characterized by generalized lymphadeno-
pathy (GLA)), alimentary (characterized by infiltration
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ABSTRACT
This study reviews the medical records of 56 dogs diagnosed with lymphoma based on the
cytological and/or histological results between January 1, 2009 and December 31, 2010. Most of the
dogs were middle-aged to old, and were diagnosed with multicentric lymphoma (ML) (n=36). The
majority of the dogs were presented in stages III to V (n=55) and substage b (n=43). A complete
blood count and serum biochemistry, urinalysis, serum protein electrophoresis, thoracic radiographs
and/or abdominal ultrasound were performed. The results correlated with previously described
results in the literature. Therapy was initiated in 80% of the dogs (n=45). After diagnosis, the median
survival time of 62% of these dogs (n=28) treated with only prednisolone was 32 days (range 3 – 224
days). For 24% of the dogs (n=11) treated with chemotherapy, the median survival time was 119
days (range 11 - 273 days). Surgical resection of the macroscopic tumor was performed in the
remaining six dogs (13%). Three of these dogs received subsequent prednisolone therapy. The
median survival time of these six dogs was 47 days (range 0 – 669 days). The dogs that received
chemotherapy had significantly longer survival times than those treated with only prednisolone,
although negative prognostic factors were present in all of the cases treated with chemotherapy.
SAMENVATTING
Het medisch dossier van 56 honden met een cytologische en/of histologische diagnose van lymfoom
gesteld tussen 1 januari 2009 en 31 december 2010 werd bestudeerd. De meeste honden waren van
middelbare leeftijd of ouder en hadden multicentrisch lymfoom (n=36). De meerderheid van de honden
bevond zich in stage III tot V (n=55) en in substage b (n=43). Hematologie, serumbiochemie, urineanalyse,
serumeiwit-elektroforese, thoraxradiografieën en/of abdominale echografie werden uitgevoerd en de
resultaten kwamen grotendeels overeen met deze in de literatuur. Bij 80% (n=45) werd een behandeling
opgestart. Na de diagnose was de mediane overlevingstijd voor 62% van de honden (n=28) die enkel met
prednisolone werd behandeld, 32 dagen (3 – 224 dagen). Voor 24% (n=11) behandeld met chemotherapie
was dit 119 dagen (11 – 273 dagen). Bij de resterende zes behandelde honden (13%) werd de
macroscopische tumor verwijderd middels chirurgie. Drie van deze honden werden nadien behandeld met
prednisolone. De mediane overlevingstijd van deze zes honden bedroeg 47 dagen (0 – 669 dagen). Van de
honden die met chemotherapie werden behandeld, was de mediane overlevingstijd significant langer dan
van de honden die enkel met prednisolone werden behandeld, ondanks het feit dat negatief prognostische
factoren aanwezig waren bij alle honden die chemotherapie ondergingen.
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of the gastrointestinal tract), mediastinal and extra-
nodal (affecting any other organ or tissue). Multi-
centric lymphoma (ML) is the most common form in
dogs – accounting for more than 80% of all canine
lymphomas –, and is a clinically aggressive neoplasm
comparable to high-grade non-Hodgkin’s lymphoma
in humans (Couto, 2009; Marconato, 2011). The cli-
nical findings are strongly related to the anatomical
form. Although clinical signs and physical examina-
tion are often suggestive of LSA, a definitive di-
agnosis requires cytology, histopathology or molecu-
lar diagnostics (Couto, 2009). Once the diagnosis is
confirmed, stage and substage are determined accor-
ding to the World Health Organization (WHO) clas-
sification system reproduced in Table 1.
Treatment of LSA with multi-agent chemotherapy
protocols is initially gratifying, with response rates up
to 90% (Vail, 2010). Equally important, most owners
feel that the animal’s quality of life during treatment is
good, and do not regret pursuing palliative chemothe-
rapy (Mellanby et al., 2003; Bergmann et al., 2011).
The prognosis varies, and it is negatively influenced by
several factors, such as WHO stage V and substage b,
mediastinal location, intermediate or high histological
grade, T-cell type, previous treatment with corticoste-
roids or chemotherapy and the presence of hypercal-
cemia. Eventually, most animals die after relapse of
chemotherapy-resistant, disseminated disease (Vail and
Young, 2007; Vail, 2010; Marconato et al., 2011).
The aim of this retrospective study is to review the
medical records and to describe the signalment, clini-
cal signs, physical examination findings, laboratory
and medical imaging abnormalities, the anatomical
form, stage and substage, the therapy used and the
overall survival time of dogs with LSA at the Depart-
ment of Small Animal Medicine and Clinical Biology,
Faculty of Veterinary Medicine, Ghent University.
MATERIALS AND METHODS
Criteria for the selection of the cases
Retrospectively, the medical records of 72 dogs ad-
mitted to the Department of Small Animal Medicine
and Clinical Biology of the Faculty of Veterinary Me-
dicine (Ghent University), between January 1, 2009
and December 31, 2010 with a presumptive diagnosis
of LSA were reviewed in detail. A cytological or his-
tological diagnosis of LSA was required to be included
in the study. For a cytological diagnosis of LSA, one
of the following criteria had to be met: lymphoblasts ac-
counting for > 50% of all nucleated cells present in a
lymph node (Cowell et al., 2003), the presence of ≥ 30%
lymphoblasts and lymphocytes in bone marrow (Grin-
dem et al., 2002) or the presence of a monomorphic po-
pulation of lymphoblasts in non-lymphoid tissue (Webb
et al., 2008). Dogs with a confirmed diagnosis of acute
lymphoblastic leukemia or dogs whose medical record
was incomplete were excluded. Fifty-six dogs met the
inclusion criteria.
Procedures
The medical records were reviewed for information
collected at the first examination including signalment,
clinical signs, physical examination findings, blood
examination results (complete blood count (CBC), se-
rum biochemical profile, coagulation profile and serum
protein electrophoresis), results of urinalysis, medical
imaging, cytology, histopathology and immunopheno-
typing. The WHO clinical staging system for LSA in
domestic animals was used to determine stage and sub-
stage in all of the 56 cases. Treatment, survival time af-
ter diagnosis, response to therapy and adverse events as-
sociated with treatment were reviewed for the 20 dogs
followed up at the clinic. The response to chemotherapy
was classified by the use of the following categories:
complete remission (CR: 100% reduction of all mea-
surable lesions), partial remission (PR: ≥ 50% but
<100% reduction in size of all measurable lesions),
stable disease (SD: < 50% reduction in size of all mea-
surable lesions or no change and no new neoplastic le-
sions), and progressive disease (PD: > 25% increase in
size or the appearance of new neoplastic lesions) (Et-
tinger, 2003). Hematologic and gastrointestinal toxico-
sis were assessed based on the medical records, apply-
ing the common terminology criteria for adverse events
(CTCAE) (Veterinary cooperative oncology group,
2004). Telephonic contact with the referring veterina-
rian and/or the owner provided additional information
regarding survival time in another 34 of the cases. Two
dogs were lost to follow-up.
Statistical analysis
The data was interpreted by means of descriptive
statistics. The results are expressed as mean ± SD with
range. Because some of the clinicopathological tests
Table 1. WHO clinical staging for domestic animals with LSA (Vail and Young, 2007; Vail, 2010).
Stage Criteria
I Single lymph node involved (or lymphoid tissue in one single organ)
II Multiple lymph nodes involved in a regional area
III Generalized lymph node involvement
IV Liver and/or spleen involved (+/- stage III)
V Bone marrow, blood and/or nonlymphoid organs involved (+/- stage I to IV)
Substage a = Without clinical signs of disease
Substage b = With clinical signs of disease
Vlaams Diergeneeskundig Tijdschrift, 2012, 81 343
were carried out at different laboratories with different
reference ranges, only the percentages of the dogs ha-




The mean age at presentation was 7.6 years ± 3.3
years (range, 1.7 to 14.4 years). The mean body weight
was 30.5 kg ± 14.1 kg (range, 4.4 to 64.5 kg). Eighteen
dogs (32.1%) were male intact, 7 (12.5%) male neute-
red, 12 (21.4%) female intact and 19 (33.9%) female
spayed. Twenty-nine breeds were represented in the
study. The breed distribution is shown in Table 2.
History, clinical signs and physical examination fin-
dings
The most common clinical signs and physical exa-
mination findings at presentation are shown in Fi-
gure 1. The duration of the clinical signs at the time of
presentation varied from 1 to 135 days, with a median
duration of 22 days. Twenty-five (44.6%) dogs had pre-
viously been treated with corticosteroids by the refer-
ring veterinarian, and one dog (1.7%) had previously
been treated with a multi-agent chemotherapy protocol
(doxorubicin, cyclophosphamide and prednisolone).
Table 2. Prevalence of dog breeds diagnosed with LSA.
Breed Total %
Labrador retriever 9 16.1
Mixed breed 8 14.3
Bernese mountain dog, Bouvier de Flandres, Golden retriever 3 each 5.4
American Staffordshire terrier, Border collie, Boxer, Flatcoated retriever,
German shepherd dog, Rottweiler 2 each 3.6
Beagle, Bullmastiff, Canadian white shepherd, Chihuahua, Dutch kooiker hound,
English bulldog, English cocker spaniel, German shorthaired pointer, Great Dane,
Griffon korthals, Maltese, Rough collie, Saint Bernard, Shar-pei,
Standard Schnauzer, Dachshund, Tibetan terrier, Welsh corgi 1 each 1.8
Table 3. Results of CBC, serum biochemistry and coagulation, plus the percentages of normal, elevated and decreased
results.
Number Normal (% of Elevated (% of Decreased (% of
of dogs tested the dogs tested) the dogs tested) the dogs tested)
Hematology
Red blood cells n=42 26 (61.9%) 1 (2.4%) 15 (35.7%)
White blood cells n=40 19 (47.5%) 18 (45%) 3 (7.5%)
► Lymphocytes n=22 14 (63.6%) 7 (31.8%) 1 (4.5%) 
► Neutrophils n=22 9 (40.9%) 12 (54.5%) 1 (4.5%) 
Thrombocytes n=40 22 (55%)  1 (2.5%) 17 (42.5%)
Biochemistry 
Urea n=43 34 (79.1%) 8 (18.6%) 1 (2.3%) 
Creatinine n=43 37 (86%) 6 (14%) 0 
Liver enzymes n=43 20 (46.5%) 22 (51.2%) 1 (2.3%)
Total bilirubin n=9 6 (66.6%) 3 (33.3%) 0
Total protein n=43 28 (65.1%) 4 (9.3%) 11 (25.6%)
Albumin n=43 30 (69.8%) 2 (4.7%) 11 (25.6%)
Calcium n=24 19 (79.2%) 5 (20.8%) 0
Coagulation
PTa n=9 8 (88.9%) 1 (11.1%) 0
aPTTb n=9 8 (88.9%) 1 (11.1%) 0
D-dimers n=8 3 (37.5% 5 (62.5%) 0
Fibrinogen n=8 6 (75%) 2 (25%) 0
aProthrombin time
bActivated partial thromboplastin time
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Clinicopathologic findings
The blood examination results are described in Table
3. In nine cases (16.1%), no blood examination was per-
formed. Seven of these dogs suffered from ML and pre-
sented with generalized lymphadenopathy (GLA). The
cytological examination of fine needle aspirations (FNA)
of the peripheral lymph nodes was diagnostic, after
which the dogs were euthanized (n=3), or palliative tre-
atment with corticosteroids was started (n=4). The two
other cases, in which no blood examination was perfor-
med, were a dog with central nervous system LSA that
was euthanized immediately after diagnosis and a dog
with laryngeal LSA that was treated with corticosteroids.
Serum protein electrophoresis was performed in six
dogs (10.7%) and showed a monoclonal gammopathy in
two of them (33.3%). Tests for tick-borne diseases were
performed in four of the dogs (7.1%), and all results
were negative.
The urine of 15 dogs (26.8%) was analysed. Isosthe-
nuria (1.007 ≤ SG ≤ 1.015) was present in six (40%) and
hypersthenuria (SG > 1.015) in nine of the dogs (60%).
The urine protein to creatinine ratio was increased (>
0.5) in four of the 15 dogs (26.7%).
Medical imaging
The most commonly detected abnormalities on tho-
racic radiographs and abdominal ultrasound are pre-
sented in Table 4.
Cytology, histopathology and molecular diagnostics
The diagnosis of LSA was based upon the cytolo-
gical results in 44 of the dogs (78.6%). Fine needle as-
pirates of peripheral lymph nodes were diagnostic for
LSA in 33 of these 44 cases (75%). The cytological re-
sults of abdominal lymph nodes provided a definitive
diagnosis of LSA in four cases (9.1%). Extranodal si-
tes or fluids that were examined microscopically to
confirm the diagnosis or to determine the clinical stage
were the spleen (n=5; 11.4%), the liver (n=4; 9.1%), an
abdominal mass of unknown origin (n=3; 6.8%), the
kidney (n=2; 4.5%), the stomach, the small intestines,
a cranial mediastinal mass, a laryngeal mass, pleural ef-
fusion and cerebrospinal fluid (1 each, 2.3%). Bone
marrow aspirations were performed in five dogs and
cytology revealed lymphoma in two dogs.
Histopathology provided the diagnosis in fourteen
of the dogs included in this study (25%). The tissues
examined were mucocutaneous lesions (n=5; 35.7%),
peripheral lymph nodes (n=3; 21.4%), abdominal
lymph nodes (n=2; 14.3%) and splenic nodules (n=2;
14.3%). Biopsies of stomach, small intestines and la-
rynx were diagnostic in one dog each (7.1%). In two of
the dogs (14.3%), the histopathological results indica-
ted low-grade or indolent LSA. One of these dogs had
splenic marginal zone LSA, and the other one had epi-
theliotropic lingual LSA.
In total, two dogs (3.6%) had both a cytological and
a histological confirmation of LSA. In one of them,
FNA of enlarged submandibular lymph nodes was dia-
gnostic of LSA. In addition, biopsies of oral mucosal
lesions were taken and revealed mucocutaneous LSA.
The other dog with gastric perforation had FNA of ab-
dominal lymph nodes, and partial gastrectomy was
performed during emergency surgical exploration.
Both the cytological results of the lymph nodes and the
histological results of the gastric wall were diagnostic
of LSA.
Immunophenotyping was performed in 17 dogs
(30.4%), either through immunocytochemistry, im-
munohistochemistry or flow cytometry. The T-cell type
predominated (n=10; 58.8%). In the remaining dogs,
Table 4. Most common medical imaging findings.
Thoracic radiograph findings Number % of dogs
(n=29) of dogs tested
No abnormalities 13 44.8
Diffuse interstitial lung pattern 7 24.1
Alveolar lung pattern 5 17.2
Suprasternal or tracheobronchial LA* 5 17.2
Pleural effusion 5 17.2
Cranial mediastinal mass 3 10.3
Abdominal ultrasound findings Number % of dogs
(n=28) of dogs tested
No abnormalities 4 14.3
Abnormal spleen (hypoechoic, splenomegaly, nodules) 15 53.6
Abdominal LA 14 50
Abnormal liver (hypoechoic, hepatomegaly) 9 32.1
Gastrointestinal wall thickening and/or loss of layering 7 25
Ascites 3 10.7
Abdominal mass of unknown origin 3 10.7
* LA: lymphadenopathy
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Table 5. Treatment options and correlated survival times.
Number MSTa Range Lost to CRb PRc
of dogs (days) (days) follow-up
General outcome 56 (100%) 31 0-383 2
Euthanasiad 11 (19.6%) - - -
Prednisolone only 28 (50%) 32 3-224 1
Surgery 6 (10.7%) 47 0-669 1
Chemotherapy 11 (19.6%) 119 11-273 -
► L-VCA-Short 6 (10.7%) 109 11-273 - 2 (33.3%) 2 (33.3%)
► Single-agent 5 (8.9%) 31 129 69-272 - 3 (60%) 1 (20%)
a Median survival time
b Complete remission
c Partial remission
d Euthanasia or death before specific treatment could be initiated
Figure 1. Clinical complaints and most common physical examination findings at presentation of 56 dogs with LSA.
(a) Temperature > 39.2°C
(b) Respiratory rate > 40/minute
(c) Heart rate > 140/minute
% of dogs presenting with this complaint









Painful on abdominal palpation
(b) Tachypnoea/panting
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LSA was B-cell type (n=7; 41.2%). Null-cell type LSA
was not represented in the study.
Anatomical form, stage and substage
The distribution of the study population concer-
ning anatomical location, stage and substage is shown
in Figures 2, 3 and 4.
Concurrent diseases
Other diseases possibly related to LSA that were
diagnosed at the time of presentation or that develo-
ped shortly thereafter, were disseminated intravascu-
lar coagulation, micro-angiopathic hemolytic ane-
mia, immune-mediated hemolytic anemia,
immune-mediated polyarthritis, chronic kidney di-
sease (CKD), lymphocytic-plasmocytic enteritis
(LPE) and endocarditis, each found in two dogs
(3.6%). The source of endocarditis in one of these
dogs was most likely an infection of the oral cavity
that occurred secondary to the lesions caused by mu-
cocutaneous LSA. One dog (1.8%) with intestinal
LSA presented with an intestinal intussusception, and
one dog (1.8%) with gastric LSA suffered from a
septic peritonitis secondary to a ruptured gastric ulcer.
One dog (1.8%) with stage V ML and severe throm-
bocytopenia (24,000 platelets/µl) had a pulmonary
bleeding. Another dog (1.8%) with ML suffered from
inflammation of muscle and fat tissue in the lumbo-
sacral epidural area. Bilateral laryngeal paralysis and
uveitis were seen in one dog each (1.8%).
Treatment and outcome
The median survival time (MST) and range for
each treatment option applied to the dogs of the study
are shown in Table 5.
Surgery was performed in six dogs: three of them
with splenic LSA underwent splenectomy, two of the
dogs with mucocutaneous LSA had nodulectomy, and
in one dog with gastric LSA, partial gastrectomy was
performed. Three of the surgically treated dogs were
subsequently treated with prednisolone. One of the
dogs with lingual low-grade LSA was still alive 383
days after the nodulectomy, and one of the dogs with
splenic low-grade LSA was still alive 669 days after the
splenectomy. 
The L-VCA-Short protocol shown in Table 6 was
used in six of the eleven cases that underwent chemo-
therapy. Five of them suffered from ML and one from
mediastinal LSA.  The five remaining dogs were trea-
ted with single-agent chemotherapy. One of these dogs
with ML was treated with doxorubicin (30 mg/m2 IV
every 3 weeks), one dog with ML stage V or leukemia
(bone marrow examination was not performed) with
chlorambucil (0.2 mg/kg/d PO) and the three remaining
dogs (two of these dogs with mucocutaneous and one
with intestinal LSA) with lomustine (66 - 74 mg/m2 PO
every three weeks). 
The side effects in ten of the eleven dogs treated with
chemotherapy were studied, and occurred in six of the
dogs (60%). Sterile hemorrhagic cystitis (SHC) was
seen in one dog receiving cyclophosphamide, and he-
patopathy occurred in two cases (20%) (in one case af-
ter treatment with lomustine and in the other case after
vincristine administration). Neutropenia was present
during the course of chemotherapy in three of the ten
dogs (30%). Neutropenia was classified as CTCAE
grade 2 in two dogs (once after lomustine and once af-
ter doxorubicin treatment) and as grade 4 in one dog (af-
ter cyclophosphamide administration). Thrombocyto-
penia was present in one dog (10%; grade 3) after
vincristine administration. Gastrointestinal toxicosis oc-
curred in four dogs (40%; grade 1 in three of the dogs,
grade 4 in one of the dogs). In all four cases, gastroin-
testinal complaints started within five days after the first
vincristine administration of the L-VCA-Short protocol.
In two of these dogs, one more episode of gastrointesti-
nal toxicosis was seen during the course of chemotherapy
treatment – in one case, after doxorubicin and in the
other case, after cyclophosphamide administration.
Figure 2. Percentage of dogs presenting with each
anatomical form.







Figure 3. Stage at the time of presentation. Figure 4. Sub-
stage at the time of presentation.
Vlaams Diergeneeskundig Tijdschrift, 2012, 81 347
Table 6. L-VCA-Short protocol (Vail and Young, 2007).
Week Drug Dose Week Drug Dose
1 Vincristine 0.7 mg/m2 IV 11 Vincristine 0.7 mg/m2 IV
Prednisone 2 mg/kg/day PO
2 Cyclophosphamide 250 mg/m2 IV 12 Cyclophosphamide 250 mg/m2 IV
Prednisone 1.5 mg/kg/day PO
3 Vincristine 0.7 mg/m2 IV 13 Vincristine 0.7 mg/m2 IV
Prednisone 1 mg/kg/day PO
4 Doxorubicin 30 mg/m2 IV 14 Doxorubicin 30 mg/m2 IV
Prednisone 0.5 mg/kg/day PO
5 No treatment 15 No treatment
 
6 Vincristine 0.7 mg/m2 IV 16 Vincristine 0.7 mg/m2 IV
7 Cyclophosphamide 250 mg/m2 IV 17 Cyclophosphamide 250 mg/m2 IV
8 Vincristine 0.7 mg/m2 IV 18 Vincristine 0.7 mg/m2 IV
9 Doxorubicin 30 mg/m2 IV 19 Doxorubicin 30 mg/m2 IV
10 No treatment
DISCUSSION
In the present study, the most commonly affected
breed was the Labrador retriever, accounting for 16.1%
of all the cases. However, this breed had previously not
been identified to be at an increased risk for developing
LSA. A possible explanation is the difference in breed
popularity between different countries, with the La-
brador retriever being a popular breed in Belgium.
The most frequent clinical signs observed in the pre-
sent study were non-specific signs and/or a peripheral
lymphadenopathy (LA). Other clinical signs and phy-
sical examination findings varied widely with the ana-
tomical form present. In case of regional peripheral LA,
the mandibular and prescapular lymph nodes were
most commonly affectted. Polyuria and polydipsia
(pu/pd) were observed in 26% of the dogs, and could
be attributed to hypercalcemia (n=3), hepatopathy
(n=4), previous treatment with corticosteroids (n=3) or
furosemide (n=1) or CKD (n=2).
Hematologic and serum biochemical abnormalities
may vary widely in dogs with LSA, and are not dia-
gnostic (Couto, 2009). The anemia and thrombocyto-
penia found in a large percentage of the dogs of the pre-
sent study were related to bone marrow infiltration,
paraneoplastic immune-mediated destruction, splenic
infiltration and/or chronic disease. Regenerative ane-
mia may also be associated with concomitant blood
loss (Couto, 2009; Vail, 2010). However, in one dog
with bilateral renal LSA, polycythemia was present (he-
matocrit 72.8%, reference range 37%-55%). Polycy-
themia has been described in two dogs with renal T-cell
LSA. The proposed pathogenesis is a combination of
two mechanisms: the paraneoplastic production of
erythropoietin by the tumor and an increased erythro-
poietin production by the remaining normal kidney cells,
induced by local hypoxia due to compression of their
vasculature (Durno et al., 2011). In dogs with leukocy-
tosis, a differential cell count should be obtained to
identify which leukocyte populations are involved.
Lymphocytosis is known to occur in 20% of LSA cases
and is usually of low magnitude (<10,000-12,000/µl)
(Vail and Young, 2007; Couto, 2009). However, in the
present study, lymphocytosis was present in seven
dogs (31.8%) and the lymphocyte count exceeded
12,000/µl in four of them. These four dogs were clas-
sified as stage V ML cases, but leukemia could not be
excluded with certainty in three of them, since bone
marrow was only examined in one of these dogs. On
serum biochemistry, the most common abnormalities
are usually hypercalcemia and changes due to organ
failure secondary to tumor infiltration (Couto, 2009,
Vail, 2010). The increase in serum liver enzymes or bi-
lirubin concentrations seen in over 50% of the dogs of
the present study could be due to hepatic parenchyma
infiltration and/or corticosteroid administration. The
azotemia present in six dogs (16%) could be due to tu-
mor infiltration, but also to dehydration, pre-existing
CKD or hypercalcemic nephrosis (Vail, 2010).
Abdominal ultrasound is an important tool in the
diagnosis and staging of LSA, as the presence of
LSA can be confirmed with ultrasonographic guided
FNA (Vail and Young, 2007). It was performed in
50% of the dogs of this study, more specifically in pa-
tients with gastrointestinal signs or palpable organo-
megaly on abdominal palpation or when serum bio-
chemistry abnormalities were present, indicating
possible organ involvement. It was not used as a stan-
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dard staging procedure, as there is no prognostic dif-
ference between cases of ML with or without hepatic
and/or splenic infiltration (i.e. stage IV or stage III ML)
(Vail and Young, 2007; Vail, 2010).
Thoracic radiographs were performed in 50% of the
dogs of the study population - either for diagnostic pur-
poses (if the dog showed respiratory signs), or to de-
termine the prognosis in case the owners were consi-
dering chemotherapy. This imaging modality is
prognostically relevant, as there is a negative correla-
tion between the presence of a mediastinal LA on the
one hand and the remission duration and survival time
on the other (Starrak et al., 1997). In a retrospective
study of 84 dogs with ML, the most common abnor-
malities on thoracic radiographs were suprasternal LA
(40%), pulmonary infiltration (37%), tracheobronchial
LA (33%), cranial mediastinal LA (26%) and pleural
change (23%). Pulmonary infiltration was suspected
when a generalized interstitial pattern was present,
most often reticular or micronodular (Blackwood et al.
1997).  In the present study, possible pulmonary infil-
tration was present in 41.3% of the dogs in which ra-
diographs were performed. However, the diffuse in-
terstitial changes could have been related to age or
chronic effects of air pollutants. It is also possible that
dogs with ML and with unremarkable radiographs do
have pulmonary involvement, which can be detected
with bronchoalveolar lavage (Hawkins et al., 1993).
Bronchoalveolar lavage was not performed in the
study, and its correlation with prognosis is unknown.
Although clinical signs and physical examination
are often suggestive of LSA – especially in cases of ML
– a definitive diagnosis cannot be made without cyto-
logy, histology or molecular techniques. In 90% of
the canine ML cases, FNA of peripheral lymph nodes
will suffice. This is a minimally invasive and inex-
pensive technique for diagnosing LSA (Couto, 2009).
In the present study, the cytological result of peripheral
lymph nodes was conclusive in 33 of the 36 dogs with
ML (91.7%). If the result of FNA of peripheral lymph
nodes is inconclusive, biopsy of these lymph nodes
should be performed. Histopathology of peripheral
lymph nodes provided the diagnosis in three more
dogs with ML. Preferably, the entire lymph node is re-
moved (excisional biopsy) so the architecture of the
node and the integrity of the capsule can be assessed
(Vail and Young, 2007). If this is not an option, an in-
cisional or Tru-cut biopsy can be performed (Ettinger,
2003). 
Immunophenotyping is important as the T-cell
phenotype correlates with a poorer prognosis in dogs
with LSA (Vail and Young, 2007; Rebhun et al.,
2010). Although B-cell LSA has been reported to ac-
count for 60% to 80% of all cases (Vail and Young,
2007), the T-cell phenotype predominated in the pre-
sent study (58.8%). This can partially be explained by
the fact that in the five cases of cutaneous LSA, biopsy
and subsequent immunophenotyping were performed.
This form of LSA is most classically represented by
epitheliotropic T-cell LSA, also called mycosis fun-
goides (Bryan, 2010). These five dogs represent half of
the cases of T-cell LSA of the present study.
Recently, the WHO classification, based on histolo-
gical and immunophenotypically characteristics, has
been applied to canine lymphomas (Valli et al., 2011).
This classification system can aid in the future to better
predict prognosis and therapeutic options.
The most common anatomical form in this study
was ML, accounting for 64.3% of the cases. This per-
centage is less than the percentages described in the li-
terature (i.e. 80% or more) (Couto, 2009; Vail and
Young, 2010). The hypothesis is that the multicentric
form is less frequently sent to a referral hospital than
other forms of LSA. Additionally, 77.8% of the dogs
with ML of the present study were classified as WHO
substage b. This is in contrast with the 10% to 25% re-
ported in previous articles (Keller et al., 1993; Vail et
al., 1996; Garrett et al., 2002). This could be due to the
fact that LSA is nowadays more readily detected and
treated by practitioners, and especially more severe
cases (i.e. clinically ill dogs) are referred to hospitals.
The most frequently encountered extranodal form in
the present study was mucocutaneous lymphoma. The
type of lesions varied from depigmentation, erythema
and desquamation to papules, plaques and nodules of
the skin, mucocutaneous junctions and oral mucosa. It
is important to realise that the cutaneous form of LSA
may mimic practically any primary or secondary skin
and mucosal lesion and is therefore called the “great
imitator” (Couto, 2009). 
In the present study, 98.2% of the dogs were pre-
sented in stage III, IV or V, which is more than the 80%
reported in the literature (Vail and Young, 2007). The
suspected reason for the large number of dogs presen-
ted at the Department of Small Animal Medicine and
Clinical Biology, Faculty of Veterinary Medicine,
Ghent University  with late stage disease, is that it is a
referral hospital. It should be noted that not every dog
of the study was submitted to medical imaging or bone
marrow examination. Therefore, underestimation of
the clinical stage might have happened in some of the
dogs with stage III disease. It is a well-known pheno-
menon that dogs are assigned a higher stage, as more
sensitive staging methods have been introduced. This
so-called stage migration makes it difficult to compare
response to treatment between studies that apply dif-
ferent staging techniques. Ideally, a standard protocol
should be developed to stage dogs with LSA (Flory et
al., 2007). 
When left untreated, the expected survival time for
dogs with LSA is four to six weeks (Vail, 2010). There
are several different therapeutic strategies for LSA, but
it is important for both the clinician and the owner to
realise that in most cases, treatment of LSA is not cu-
rative. The main goals are to offer palliative treatment
that improves the quality of life by diminishing the cli-
nical signs and to prolong the lifespan. The golden stan-
dard for the treatment of LSA is the use of systemic
chemotherapy (Vail and Young, 2007; Vail, 2010; Mar-
Vlaams Diergeneeskundig Tijdschrift, 2012, 81 349
conato, 2011). Even in cases of stage I nodal or extra-
nodal LSA, systemic spread of the diseases is to be ex-
pected within weeks or months after diagnosis (Couto,
2009). In general, dogs treated with chemotherapy are
able to enjoy a reasonable quality of life and most of
them only experience mild side effects that can usually
be treated at home (Mellanby et al., 2003). Combina-
tion chemotherapy protocols are superior to single-
agent protocols. Most multi-agent chemotherapy proto-
cols are modifications of CHOP protocols used in human
medicine for people with high-grade LSA, consisting of
cyclophosphamide (C), doxorubicin (hydroxydaunoru-
bicin, H), vincristine (Oncovin, O) and prednisone (P)
(Vail and Young, 2007). Many variations of this protocol
are available, all of which have very similar disease-free
intervals and overall survival times (Vail, 2010). The
protocol most commonly used at our Department of
Small Animal Medicine and Clinical Biology is the L-
VCA-Short protocol. L-asparaginase is not administered
in week one, as several studies have proven that adding
L-asparaginase does not significantly improve the re-
mission rates and duration. Moreover, it is a drug best re-
served for rescue protocols (Vail and Young, 2007). The
expected remission rates are 60% to 90% CR, and the
expected MST is 275 days for dogs with ML (Hosoya
et al., 2007; Couto, 2009; Vail, 2010). However, the re-
misson rates and MST were lower for six of the dogs
of the present study. A possible explanation for five of
the cases is that one or more of the following negative
prognostic factors were present: stage V, substage b, T-
cell type, mediastinal LA or previous treatment with
corticosteroids. One of the five dogs additionally suf-
fered from endocarditis and thrombocytopenia, and
died eleven days after the diagnosis of LSA was made.
In only one of the six cases, none of the negative prog-
nostic factors were present at the time of diagnosis, and
the dog survived for another 273 days.
Sometimes, clients lack the financial resources or
the time to pursue a multi-agent chemotherapy proto-
col. In those cases, single-agent therapy is an option.
Doxorubicin is the most effective and most commonly
used drug for single-agent chemotherapy in dogs with
LSA. It is administered intravenously five times with
three weeks interval and may induce CR in 50% to
85% of the cases with an MST of seven months (Simon
et al., 2008; Chun, 2009; Vail, 2010). One dog with ML
of the study was treated with this protocol, and had a
survival time of 129 days. However, the dog had pre-
viously been treated with a multi-agent chemotherapy
protocol by the referring veterinarian. In cases of epi-
theliotropic LSA, lomustine (CCNU) is frequently
used (Risbon et al., 2006; Williams et al., 2006; Vail,
2010).
Side effects in this study related to chemotherapy
were present in six dogs (60%). SHC from cyclophos-
phamide (Chun, 2009) was encountered in one of these
dogs. To prevent SHC, furosemide (1 mg/kg IV) is ad-
ministered simultaneously with cyclophosphamide,
and owners are advised to encourage water intake and
allow their dogs out to urinate frequently for three
days after drug administration. After the development
of SHC, the administration of cyclophosphamide is dis-
continued. In the present study, serum liver enzymes
concentrations were increased in one of the dogs trea-
ted with lomustine. Hepatopathy is a well-recognized
side effect of lomustine treatment (Kristal et al., 2004).
In case of grade 2 (1,000-1,499/µl) or grade 4 (<500/µl)
neutropenia,  the subsequent chemotherapy admini-
stration was postponed, and the dose was reduced by
20% in three dogs of the present study. Dose reduction
by 20% is only recommended if the neutrophil count
is ≤500/µl at its lowest point or <1500/µl at the time the
next treatment is scheduled (Vail, 2009). It has been re-
ported that reducing the dose by 20%, the efficacy of
the chemotherapy is reduced by 50% (MacDonald,
2009). The dog with grade 4 neutropenia of the present
study received enrofloxacin (5 mg/kg/day PO) for se-
ven days. Treatment with a broad-spectrum antibiotic
should only be started if the neutrophil count is
<1,000/µl, as most companion animals have a low risk
of infection as long as their neutrophil count remains
greater than 1000/µl (Vail, 2009). Vomiting was trea-
ted with maropitant (1 mg/kg SQ once and 2
mg/kg/day PO for two to four days) in three cases, and
prophylactic maropitant therapy was given (1 mg/kg
SQ once) together with vincristine administrations. In
the fourth case of gastrointestinal toxicosis, hospitali-
sation and fluid therapy were required. This dog suf-
fered from grade 4 gastrointestinal toxicosis and grade
3 thrombocytopenia, but was diagnosed with endo-
carditis, and euthanized.
In 50% of the cases included in the present study,
the owners preferred treatment with corticosteroids
only. When excluding the dogs that were euthanized af-
ter diagnosis or that had already died before treatment
could be initiated, the group treated with prednisolone
only accounted for 62% of all the dogs of the study. In
these cases, it is important to inform clients that dogs
which previously received corticosteroid therapy, are
more likely to develop drug-resistant disease if che-
motherapy would be considered at a later time (Vail,
2010). It is advised not to start corticosteroid treatment
more than 24 to 48 hours prior to starting the chemo-
therapy. Another disadvantage of the pre-treatment
with corticosteroids, is that it may mask the disease
and, lead to inaccurate diagnosing or staging at the re-
ferral hospital (Ettinger, 2003). Nevertheless, almost
50% of all the dogs of the present study had received
corticosteroids prior to being referred, and hence before
a definitive diagnosis was established and a therapy
was chosen. The MST of the dogs treated with predni-
solone in the study (32 days) was comparable to the ex-
pected survival time of one to two months in the litera-
ture. The MST for the dogs treated with chemotherapy
was significantly longer than for the dogs treated with
corticosteroids (P = 0.014).
In two dogs (3.6%) presented without any clinical
signs related to LSA, the histological results revealed
the presence of indolent LSA – one splenic and one lin-
gual. Indolent or low-grade LSA is a type of LSA cha-
racterized by a low mitotic rate and subsequently a
slow clinical progression with a long disease free in-
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terval and survival time. Most cases of canine indolent
LSA are B-cell tumors, most commonly nodal or sple-
nic. They are not rare, but their incidence is unknown
(Valli et al., 2006). A study describing five dogs with
splenic marginal zone LSA, showed that dogs under-
going splenectomy and subsequent systemic chemo-
therapy had long disease free intervals, and eventually
died of causes unrelated to lymphoma (Stefanello et al.,
2011). Another recent study containing 75 dogs with in-
dolent lymphoma led to the conclusion that systemic
treatment does not influence survival, but that further
prospective trials are warranted. The overall MST for
dogs of that study was 4.4 years (Flood-Kapnik et al.,
2012).
CONCLUSION
The results of the present study for signalment, cli-
nical signs and diagnostic techniques correlate well
with the previously described results in the literature.
At referral hospitals however, the majority of dogs
tend to present in late stages and substage b. Treatment
with prednisolone was chosen by 50% of the owners or
in 62% of the cases where therapy was initiated. The
dogs that received chemotherapy had significantly lon-
ger survival times than those treated with prednisolone
only, although negative prognostic factors were present
in the cases treated with chemotherapy.
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